JD Health posts strong Q3 2025 growth in unaudited results

JD Health International Inc. reported a significant performance improvement in its unaudited third quarter of 2025. Revenue increased by 28.7% to RMB17,119,726, up from RMB13,302,050 in the same period of 2024. Operating income saw an even more dramatic rise of 125.3%, reaching RMB1,243,290 compared to RMB551,733 year-over-year.

Profit for the period nearly doubled, surging by 97.2% to RMB1,838,503. Non-IFRS operating income also climbed by 59.9% to RMB1,377,755, and non-IFRS profit for the period grew by 42.4% to RMB1,902,237. These figures highlight robust financial health and operational efficiency.

Operationally, JD Health strengthened its market position by entering strategic cooperation agreements with major pharmaceutical companies like Eli Lilly and Bayer China. The company also debuted innovative drugs online and partnered with medical device brands to establish an intelligent interconnected ecosystem alliance focused on smart blood glucose management, aiming to expand into broader health management solutions.